Iza-Bren Reports 11.14-Month PFS in Later-Line EGFR-Mutated NSCLC

Iza-Bren reported an 11.14-month PFS in EGFR-mutated non-squamous NSCLC that progressed after third-generation EGFR TKI treatment, which the article describes as the longest second-line PFS. PANKU-Lung01 is a randomized phase III study. The first-in-class bispecific ADC targets EGFR and HER3, linking the topoisomerase I inhibitor Ed-04 through a tetrapeptide cleavable linker.